Proffered Paper - Sarcoma
LINK to Proffered Paper - Sarcoma
1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study
The abstract concludes: Pembrolizumab shows high levels of prolonged activity in selected subtypes of rare sarcomas.
LBA67 - TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas
The abstract concludes: Combination of T+D has activity in STS. Updated efficacy and biomarker analyses will be presented at the meeting.
LBA68 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
The abstract concludes: Despite a PFR at 8 weeks lower than expected, this randomized non comparative study shows a promising signal of benefit of REG in relapsed ES, with a median of PFS of 11.4 weeks, and a moderate toxicity.
1620O - Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
The abstract concludes: TK216 was well tolerated and showed encouraging early evidence of anti-tumor activity in a patient population with limited or no treatment options.